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rise. The World Health Organization estimated global
annual gonorrhea cases of 62 million in 1999. Gonorrhea
infection may increase susceptibility to and transmission of
human immunodeficiency virus (HIV). In addition, due to
sharing of same transmission route and overlapping risk
groups, gonorrhea may serve as a risk marker for infection
of HIV and other sexually transmitted infections. In Taiwan,
according to Statistics of Communicable Diseases and
Surveillance of Taiwan-CDC, 2265 new cases were reported
for 2010, with an incidence of 9.79 per 100,000 people.
In only a few decades, Neisseria gonorrhoeae has rapidly
developed resistance to multiple antibiotics, such as sulfa-
nilamide, penicillins, tetracyclines, and fluoroquinolones.
Recently, the third generation cephalosporins, or extended-
spectrum cephalosporin (ESC), currently the last remaining
treatment options in the drug pipeline, were proposed
as alternative antibiotics for treatment of gonorrhea.
However, susceptibility to all ESCs (oral and injectable) is
decreasing rapidly. Alarmingly, treatment failures with oral
ESCs have been reported in many countries. In Taiwan,
according to the 2133 isolates (representing 26.7% of the
8,001 reported cases) of gonococci-National Isolate Collec-
tion for Epidemiology (G-NICE) surveillance spanning 2008e
2011, resistant rates [criteria: European Committee on
Antimicrobial Susceptibility Testing (EUCAST) 2011, R:* Research and Diagnostic Center, Centers for Disease Control,
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doi:10.1016/j.jfma.2012.03.004Minimum Inhibitory Concentration (MIC)  0.25 mg/L and
Clinical And Laboratory Standards Institute (CLSI) 2011, S:
MIC  0.25 mg/L] to the oral cephalosporin, cefixime was
2.63% for MIC 0.25 mg/L, while for injectable cephalo-
sporin, ceftriaxone was 0% for MIC  0.25 mg/L. The
maximum MIC was 0.5 mg/L and 0.19 mg/L for cefixime and
ceftriaxone, respectively (our unpublished G-NICE surveil-
lance data).
Molecular epidemiology study employing molecular
typing methods such as N gonorrhoeae multiantigen
sequence typing (NG-MAST) or serotyping in conjunction
with sequencing the penA allele encoding penicillin-binding
protein 2 and other resistance determinants (mtrR, penB,
ponA, and pilQ) is helpful in tracing the resistant clones.1
Recent studies have indicated that most of the gono-
coccal isolates with decreased susceptibility to the ESC
belongs to a few specific major clones. In Taiwan, the
majority of cefixime-reduced susceptible strains belong to
related clones containing NG-MAST type10 tbpB and mosaic
types X penA allele such as sequence type (ST) 835, 2180,
and ST2253. These clones are multidrug resistant (MDR)
with a high percentage of resistance rate to penicillin,
tetracycline, and ciprofloxacin, and mostly circulate in
high-risk homosexual or bisexual sexual networks.2
More recently, global rapid spread of ESC-reduced
susceptible ST1407 and related STs that share the tpbB
allele (allele 110), but with different por alleles (por
908 related) and harbor mosaic penA allele types
XXXIV have been reported in Japan3 and in Europe4e6, such
as England and Wales, Sweden, the Netherlands, Norway,& Formosan Medical Association. All rights reserved.
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been found in the United States, Australia, and many
European countries. The threat is imminent with increasing
reports on MDR ST1407 strains render ESC treatment failure
in many European countries,7,8 such as France, Sweden,
England and Norway.
The emergence of MDR ST1407 with decreased suscep-
tibility to ESCs, such as ST1407, threatens to erode the last
remaining effective agents for treatment of gonorrhea. The
rapid spread of these clones might be facilitated by high-
risk sexual behavior and should be monitored closely to
identify potential treatment failure. Increasing frequency
of MDR gonococci with reduced susceptibility to ESC espe-
cially in some high-risk groups such as men who have sex
with men has been noted.9 Continuous and global
concerted surveillanceare paramount to trace the emer-
gence, introduction, and transmission of specific strains as
well as the sexual networks they circulate. The finding that
these specific clones may transmit across national bound-
aries and between different sexual networks highlights the
need for undertaking intervention as well as risk-reduction
consultation in such core-risk groups.10
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